2026-08-21 · petrelintide, ZP8396, Zealand Pharma, amylin, amylin analog, next-generation obesity drug, obesity pipeline

What is petrelintide?

Petrelintide (development code ZP8396) is an investigational long-acting amylin analog from Zealand Pharma (Copenhagen), given as a once-weekly subcutaneous injection. It is the only amylin monotherapy in active Phase 2 obesity development in the world in 2026. Amylin is a satiety hormone the pancreas releases alongside insulin, and petrelintide is a synthetic long-acting version engineered to mimic that satiety signal for a full week from one weekly injection, without touching the GLP-1 receptor. It is not FDA-approved.

How is petrelintide different from CagriSema?

CagriSema is a fixed-dose combination of two separate peptides — semaglutide 2.4 mg (a GLP-1 agonist) and cagrilintide 2.4 mg (a long-acting amylin analog) — co-administered in one weekly injection. Petrelintide is a single amylin analog with no GLP-1 component at all. CagriSema stacks amylin on top of a GLP-1; petrelintide isolates the amylin arm. That difference is why petrelintide's Phase 1b magnitude (~8.6 percent at 16 weeks) is lower than CagriSema's ~22.7 percent at 68 weeks — the GLP-1 arm accounts for most of the CagriSema magnitude.

How is petrelintide different from amycretin?

Amycretin is Novo Nordisk's single-molecule amylin plus GLP-1 co-agonist — one peptide that activates both receptors. Petrelintide activates only the amylin receptor. Amycretin is the amylin-plus-GLP-1 template built into one molecule; petrelintide is the amylin arm on its own. Amycretin's Phase 1b magnitude (~13.1 percent at 20 weeks SC) is higher than petrelintide's Phase 1b magnitude because amycretin engages both satiety pathways. Petrelintide's clinical value is for patients who tolerate amylin biology but not GLP-1s.

When will petrelintide be FDA-approved?

The realistic earliest US availability is 2029 to 2030. Zealand Pharma's Phase 2 obesity program is a 52-week dose-finding trial with a topline readout expected in 2026. A Phase 3 obesity program, contingent on Phase 2 outcome, would then run through 2027 to 2028, with an FDA submission plausible in 2028 to 2029 and a standard 10 to 18 month FDA review after that. No legitimate US access route exists before then — petrelintide is not commercially available anywhere and is not compoundable.

How much weight did people lose on petrelintide in Phase 1b?

In the Zealand Pharma Phase 1b dose-finding program in adults with obesity or overweight-with-comorbidity, mean weight loss over 16 weeks ranged from roughly 5 percent at lower doses to roughly 8.6 percent at the top dose in the range tested, with a clear dose-response. The 16-week window is short and the weight-loss curve had not plateaued, so the 52-week Phase 2 number is expected to be higher but will not be known until the mid-2026 topline readout.

Is petrelintide better tolerated than semaglutide?

The Phase 1b tolerability picture was favorable versus early-titration semaglutide in cross-trial comparison: nausea roughly 15 to 20 percent at higher doses versus roughly 25 to 35 percent for semaglutide at equivalent early titration, plus lower rates of vomiting and diarrhea. The definitive tolerability comparison requires a head-to-head Phase 3 trial, which does not exist. The amylin class as a whole has produced lower GI-event rates than the GLP-1 class in early data (Enebo 2021 Lancet), but cross-trial numbers overstate certainty.

Can I get compounded petrelintide?

No. Petrelintide is a proprietary long-acting peptide amylin analog belonging to Zealand Pharma, has never been on the FDA drug-shortage list, and has no legitimate 503A or 503B compounding pathway. No compounding pharmacy, telehealth clinic, or research-peptide vendor has legal access to the molecule. Anything sold in 2026 under the name petrelintide or ZP8396 is mislabeled, an unrelated compound, or counterfeit and should not be injected. See our compounded semaglutide and tirzepatide safety guide for the 2026 enforcement landscape.

Is petrelintide safe for someone with a history of pancreatitis?

There is no established amylin-class link to pancreatitis, unlike the GLP-1 class which carries a pancreatitis note in its FDA labels. On mechanism, an amylin analog acts primarily through hindbrain amylin receptors in the area postrema and does not stimulate pancreatic beta-cell insulin release the way GLP-1 does. That said, petrelintide is investigational — its full safety profile will be defined by Phase 2 and Phase 3 exposure. Any decision for a patient with a pancreatitis history should be made with a prescriber, not from a webpage.

Petrelintide for Weight Loss: What Zealand Pharma’s Amylin-Only Pipeline Actually Looks Like in 2026

Petrelintide is not FDA-approved and is not sold anywhere in the United States as of August 2026 — no legitimate pharmacy, telehealth clinic, or compounding operation can supply it. It is an investigational drug from Zealand Pharma (Copenhagen), developed as a once-weekly subcutaneous injection. The molecule is a long-acting amylin analog, developed as a monotherapy for chronic weight management — and it occupies a unique slot in the 2026 pipeline: petrelintide is the only amylin monotherapy in active Phase 2 obesity development in the world.

That “amylin only” positioning is the whole story. Novo Nordisk’s cagrilintide is a similar long-acting amylin analog but is being developed almost exclusively as part of the CagriSema fixed-dose combination with semaglutide. Novo’s amycretin is a single-molecule amylin plus GLP-1 co-agonist — one peptide, two receptors. Petrelintide is the amylin arm on its own, without a GLP-1 partner. That makes it the strategically important pipeline entry for patients who tolerate amylin biology but not GLP-1s.

This page explains what petrelintide is, what the Phase 1b data actually showed, how it compares to the rest of the next generation weight loss drugs pipeline, and the honest 2026 read for US patients — including why the earliest realistic availability is 2029 to 2030 and why any online product marketed as “petrelintide” or “ZP8396” today is not the drug from the Zealand trials.

What petrelintide is

Petrelintide (development code ZP8396) is a long-acting synthetic amylin analog engineered by Zealand Pharma, a Copenhagen-based biotechnology company with a two-decade history in amylin and peptide-hormone drug discovery. Zealand’s amylin platform is the same platform that produced the cagrilintide precursor programs licensed to Novo Nordisk.

Two features define the molecule:

• Long-acting. Petrelintide is engineered for a half-life supporting once-weekly subcutaneous dosing — comparable to cagrilintide and to the weekly GLP-1s (semaglutide, tirzepatide). This is a critical practical difference from the FDA-approved amylin analog pramlintide (Symlin), which has a much shorter half-life and requires three-times-daily mealtime injections.
• Amylin monotherapy. Petrelintide activates only the amylin receptor complex. It does not activate the GLP-1 receptor, the GIP receptor, or the glucagon receptor. In a pipeline dominated by multi-receptor agonists, an amylin monotherapy is a deliberately narrow mechanistic bet.

Plain-English mechanism: Amylin is a satiety hormone the pancreas releases alongside insulin at every meal. Petrelintide is a long-acting synthetic version of amylin that mimics that satiety signal for a full week from one weekly injection, without touching the GLP-1 receptor.

Dose and route — how petrelintide sits alongside the rest of the amylin family

Petrelintide is the only pure amylin monotherapy in Phase 2 in 2026. The table below places it against the closest historical and current comparators — cagrilintide monotherapy (as a mechanism-of-action reference, no longer in active standalone development), the CagriSema fixed-dose combination, and amycretin SC (Novo’s single-molecule amylin plus GLP-1 co-agonist).

The “Contains GLP-1?” column is the practical distinction. CagriSema and amycretin both include GLP-1 receptor activation; petrelintide and cagrilintide monotherapy do not. That is why petrelintide’s expected magnitude sits below CagriSema and amycretin — the GLP-1 arm carries most of the weight-loss lift in the combination drugs. Petrelintide’s clinical value is not maximum magnitude; it is amylin biology delivered without the GLP-1 tolerability burden.

Phase 1b evidence — the dose-finding readout

Zealand Pharma’s petrelintide Phase 1b program was a 16-week dose-titration study in adults with obesity or overweight-plus-comorbidity, designed to characterize the dose-response, safety, and pharmacokinetics ahead of Phase 2. The readout was communicated through Zealand’s corporate updates and subsequent peer-reviewed publication (Kruse Hansen et al. and Zealand Pharma investor materials).

• Design: randomized, double-blind, placebo-controlled, dose-titration.
• Duration: 16 weeks.
• Dose range: approximately 0.6 mg to 9 mg once-weekly subcutaneous, with a titration schedule up from the starter dose.
• Population: adults with BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity.
• Primary endpoints: safety, tolerability, pharmacokinetics; secondary endpoint mean percent weight change from baseline.

The headline result was a clear dose-response weight-loss signal, ranging from roughly 5 percent at lower doses to roughly 8.6 percent at the top dose at 16 weeks. For amylin-monotherapy Phase 1b, in a short window, that is the expected magnitude — and, critically, the weight-loss curve had not plateaued at week 16.

Two honest qualifiers:

• Sixteen weeks is short. Long-window weight-loss trials commonly extrapolate a further 30 to 60 percent lift on the short-window signal by 52 weeks. Petrelintide’s Phase 2 (52-week) readout is expected in 2026 and will characterize what the number becomes at a full year.
• Cross-trial magnitude comparisons are indicative, not definitive. The historical amylin-only cagrilintide monotherapy Phase 2 (Lau 2021, Lancet) reported roughly 10 percent at 26 weeks on the 4.5 mg dose — a helpful mechanism anchor, but different trial, different population, different dose range.

Amylin mechanism — why an amylin analog matters as a satiety therapy

Amylin is a 37-amino-acid pancreatic peptide co-secreted with insulin from beta cells in response to meals. Its physiological role complements insulin: amylin slows gastric emptying, suppresses postprandial glucagon secretion, and produces meal-related satiety through amylin receptors in the area postrema of the hindbrain — a region outside the blood-brain barrier that GLP-1 does not primarily engage. GLP-1’s own satiety signal is generated in the hypothalamic arcuate (ARC) and paraventricular (PVN) nuclei. Two circuits, two mechanisms, anatomically distinct.

The proof-of-concept that amylin biology alone produces clinically meaningful weight loss came from the Lau 2021 cagrilintide monotherapy Phase 2 (Lancet, n=706): the 4.5 mg dose produced roughly 10 percent weight loss at 26 weeks — comparable to Saxenda 3 mg over the same window, achieved with a once-weekly injection rather than daily. That trial is the historical anchor for the amylin-only strategy that petrelintide now advances.

The additive-satiety hypothesis explains the difference between the amylin-only drugs and the combination drugs: amylin and GLP-1 target complementary satiety pathways. Adding a GLP-1 arm on top of amylin (as CagriSema does, and as amycretin does in a single molecule) produces meaningfully more weight loss than either mechanism alone at matched exposure — because the two brain circuits are additive rather than redundant. Petrelintide isolates the amylin contribution.

Why an amylin monotherapy matters clinically

A pure amylin drug is not a magnitude leader in the 2026 pipeline. Its clinical value is a specific patient population question. Three concrete groups benefit from an amylin-only option:

• Patients who cannot tolerate GLP-1 side effects. Roughly 15 to 25 percent of GLP-1 users experience intolerable nausea, vomiting, or persistent GI side effects, and a meaningful subset discontinues therapy for that reason (Wilding 2025 STEP-1 real-world adherence data, roughly 40 percent one-year discontinuation on injectable GLP-1s). An amylin-only drug offers a different tolerability profile — early data suggest lower GI-event rates than semaglutide — and a separate satiety mechanism.
• Patients with a history of pancreatitis or class-label caution. GLP-1 labels carry a pancreatitis note. Amylin analogs do not stimulate pancreatic beta-cell insulin release the way GLP-1 does and have no established pancreatitis link. Any decision here belongs with a prescriber, but a mechanistically distinct option matters when the GLP-1 class label creates hesitation.
• Patients whose weight-loss goal is modest. For a patient aiming at 5 to 10 percent total body-weight loss — not the 15 to 25 percent target of maximally-titrated GLP-1s or GLP-1/GIP duals — a lower-magnitude but better-tolerated amylin drug can be the right dose of intervention.

The definitive tolerability comparison against semaglutide or tirzepatide requires a Phase 3 head-to-head trial, which does not exist. Every side-by-side comparison in this article is cross-trial and directional, not definitive.

Six-row pipeline comparison — petrelintide vs the rest of the amylin and incretin field

The table below sets petrelintide against the closest historical and current comparators. Numbers are the highest Phase 2 or Phase 3 topline reported for each drug at the timeframes noted. Cross-trial comparisons across separate populations always overstate the certainty of the difference — the value here is the mechanism-and-magnitude map, not a ranked leaderboard.

Petrelintide is the only amylin-only drug in active Phase 2 obesity development globally in 2026 — every other amylin asset on the table is either historical (cagrilintide monotherapy, folded into CagriSema) or combined with GLP-1 (CagriSema as a fixed-dose combination, amycretin as a single-molecule co-agonist). That uniqueness is why it is watched despite trailing the combination drugs on peak magnitude.

Safety profile from Phase 1b

The Phase 1b tolerability picture was a GI-dominant profile — the expected pattern for a satiety-active hormone acting on the area postrema — but with notably lower event rates than early GLP-1 monotherapy in cross-trial comparison.

• Nausea — roughly 15 to 20 percent at higher doses, versus roughly 25 to 35 percent for semaglutide at equivalent early-titration timepoints in STEP program data.
• Vomiting — roughly 5 to 10 percent, titration-related.
• Injection-site reactions — roughly 5 to 8 percent. The calcitonin-family peptides (which amylin analogs belong to) have a known tendency for injection-site nodules; the Phase 1b rate at the doses tested was manageable but should be tracked in Phase 2.
• No cardiac signal in Phase 1b. Heart rate was neutral, consistent with amylin biology (unlike glucagon-arm dual agonists, which produce a small resting heart-rate rise).
• No thyroid C-cell tumor signal reported in the Phase 1b window. The class-defining safety questions require Phase 3 exposure.

The historical amylin-class safety anchor is pramlintide (Symlin), FDA-approved in 2005 as a T2D adjunct to insulin. Pramlintide has a two-decade post-marketing safety record. Its primary risk is severe hypoglycemia when combined with insulin — a risk that does not apply to petrelintide monotherapy in non-diabetic obesity, because petrelintide is not being developed for insulin-treated patients and does not itself lower blood glucose on the scale that would trigger hypoglycemia.

Phase 2 program and timeline

Zealand’s Phase 2 obesity program is a 52-week dose-finding trial based on the most recent public corporate disclosure. Design highlights:

• Duration: 52 weeks (the standard obesity Phase 2 endpoint).
• Primary endpoint: mean percent weight-loss from baseline at week 52.
• Secondary endpoints: waist circumference, cardiometabolic markers, patient-reported outcomes.
• Topline readout expected: 2026 (mid-to-late).

The Phase 3 obesity program is contingent on Phase 2 outcome — Zealand has not publicly announced Phase 3 protocol details or trial numbers ahead of the Phase 2 topline, which is standard practice for a Phase 2 dose-finding trial. The realistic pathway from a positive Phase 2 readout:

• Phase 3 obesity enrolment — late 2026 to 2027.
• Phase 3 obesity primary readout — 2027 to 2028 (52-week endpoint) or later for cardiovascular sub-studies.
• FDA submission — 2028 to 2029.
• FDA review — 10 to 18 months.
• Earliest realistic US availability — 2029 to 2030.

The Zealand / Novo Nordisk acquisition angle

Zealand Pharma’s amylin platform has been the subject of publicly-reported Big Pharma licensing and acquisition discussions since 2024, and Novo Nordisk has publicly disclosed interest given the mechanistic alignment with the CagriSema and amycretin programs. Novo already licensed the underlying cagrilintide molecule from Zealand under a prior agreement, and the CagriSema program is a direct Zealand-to-Novo pathway. Whether petrelintide follows the same pathway — a licensing deal, a full acquisition, or Zealand commercializing on its own with a partner — is unresolved as of publication.

Honest phrasing: petrelintide’s commercial path may run through Zealand, through Novo Nordisk under a licensing or acquisition deal, or through another sponsor — the outcome will be decided by 2026 Phase 2 data and the acquisition landscape. For patients the ownership question matters because it determines pricing, formulary placement, and prior-authorization pathways in 2029 to 2030. A Novo-owned petrelintide would inherit Novo’s payer relationships and price alongside Wegovy; a Zealand-independent commercialization would take longer to establish market access. For the current 2026 pricing landscape and Medicare Part D coverage picture, see GLP-1 cost and insurance.

What petrelintide does not do in 2026

The Phase 1b signal is genuinely promising for the amylin-only strategy, but the honest limits matter for any 2026 reader making a treatment decision.

• Not FDA-approved for any indication. No US access route exists.
• Not compoundable. Petrelintide is a proprietary long-acting peptide amylin analog, has never been on the FDA drug-shortage list, and has no legitimate 503A or 503B compounding pathway even in an emergency shortage. Do not respond to any “compounded petrelintide” or “ZP8396” grey-market vendor — the molecule is proprietary to Zealand Pharma and any product sold under that name is mislabeled, an unrelated compound, or counterfeit. See compounded semaglutide and tirzepatide safety for the 2026 enforcement landscape.
• No head-to-head data against semaglutide, tirzepatide, cagrilintide, CagriSema, or amycretin. Every side-by-side comparison in this article and elsewhere is cross-trial.
• Not for T2D as monotherapy. The established amylin analog for T2D is pramlintide (Symlin), used as an adjunct to insulin rather than as monotherapy. Petrelintide has not been filed for a T2D indication and is not being developed as a T2D drug.
• Not the highest-magnitude option in the pipeline. Retatrutide (~24 percent at 48 weeks Phase 2), CagriSema (~22.7 percent at 68 weeks Phase 3), and MariTide (~19.5 percent at 52 weeks Phase 2b) all deliver more weight loss. Petrelintide’s positioning is amylin-only tolerability, not maximum magnitude.

Practical read for US patients in 2026

If you are choosing weight-loss pharmacotherapy today, petrelintide is not on the shelf and will not be for 3 to 4 years. Wegovy and Zepbound are FDA-approved, produce durable weight loss (roughly 15 percent and 21 percent respectively at their pivotal 68- and 72-week endpoints), and switching to a next-generation drug at approval is straightforward.

If GLP-1 tolerability is the main barrier for you — persistent nausea, GI side effects, or the pattern of intolerable early-titration events — the right 2026 conversation is with your prescriber about micro-dosed titration protocols, extended titration schedules, switching molecules within the GLP-1 class, or trying a different mechanism (bupropion-naltrexone, or the amylin-adjacent bariatric surgery route for candidates) before waiting three years on an investigational drug. See GLP-1 microdosing and food noise and GLP-1s for the current 2026 tolerability-management picture.

The most useful signal to track is the mid-2026 Zealand Phase 2 topline readout. That number — the 52-week magnitude on the top dose, the tolerability picture at exposure, and the persistence of the weight-loss curve — will determine whether petrelintide advances to Phase 3, whether Novo Nordisk (or another acquirer) takes the platform, and whether the 2029 to 2030 availability window holds.

For the full 2026 map of pipeline drugs, mechanism trees, and the practical “should I wait?” protocol, see the next generation weight loss drugs pillar. For the on-label 2026 options that are actually on pharmacy shelves today, see prescription weight loss medications, semaglutide for weight loss, and tirzepatide for weight loss.